HEALTHX
HEALTHX
Each stock's 10,000-path forecast, rendered as light.
HEALTHX (HEALTHX) Stock Analysis & Case Study
Is HEALTHX a good buy? The data-driven verdict.
HEALTHX (HEALTHX) trades at ₹316,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 19/100.
On the numbers, HEALTHX (HEALTHX) high-risk on the numbers, a Downstox Snapshot Score of 19/100, weighing expensive at 513.0× earnings, ROE of 0.3%, a 38% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
HEALTHX fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is HEALTHX overvalued? HEALTHX P/E vs its sector
HEALTHX's P/E of 513.0× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers.
HEALTHX share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of HEALTHX history (-4%/yr drift, 39%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| HEALTHX 2027 | ₹170 | ₹280 | ₹465 | -12% |
| HEALTHX 2028 | ₹123 | ₹249 | ₹511 | -21% |
| HEALTHX 2029 | ₹95 | ₹222 | ₹518 | -30% |
| HEALTHX 2030 | ₹73 | ₹196 | ₹532 | -38% |
| HEALTHX 2031 | ₹57 | ₹172 | ₹522 | -46% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability HEALTHX goes up, or doubles?
The bull case for HEALTHX
- HEALTHX is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹518.
The bear case & risks
- A rich 513.0× P/E leaves a thin margin of safety if growth slows.
- Return on equity is a soft 0.3%, capital efficiency trails higher-quality peers.
- A low Piotroski F-Score of 2/9 flags weaker financial health this cycle, worth understanding why before committing.
- The probability model is cautious 12 months out, only a 38% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹95.
HEALTHX volatility & expected range, how bumpy is the ride?
Over the last 2.0 years HEALTHX compounded at -4%/year with annualized volatility of 39%. That volatility implies a 1-year 80% range of ₹170–₹465, the honest backbone behind any single price target.
HEALTHX price forecast, the full 60-month probability fan
HEALTHX price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds HEALTHX hits common targets within the simulated horizon?
Full multi-horizon detail on the HEALTHX price target & forecast page.
HEALTHX Piotroski F-Score: 2/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. HEALTHX scores 2/9,weak on the financial-strength checks.
HEALTHX MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy HEALTHX with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| ZerodhaCHEAPEST | 50.0% | 2.0× |
Compare every broker on the HEALTHX MTF page.
HEALTHX vs peers,sector comparison
About HEALTHX: sector, index & market-cap context
HEALTHX (HEALTHX) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹984 Cr. See more Nifty 500 stocks.
How the HEALTHX Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of HEALTHX's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
HEALTHX analysis, FAQs
Is HEALTHX (HEALTHX) a good buy?
On the numbers, HEALTHX (HEALTHX) high-risk on the numbers, a Downstox Snapshot Score of 19/100, weighing expensive at 513.0× earnings, ROE of 0.3%, a 38% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is HEALTHX overvalued or undervalued?
HEALTHX trades at 513.0× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the HEALTHX share price target for 2031?
HEALTHX's probability-weighted 2031 median target is ₹172, with an 80% range of ₹57–₹522 (10,000-path Monte-Carlo).
What is the probability HEALTHX doubles in 5 years?
The modelled probability of HEALTHX reaching ₹632 (2×) within 5 years is 7%.
What is the bull case for HEALTHX?
HEALTHX is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in HEALTHX?
A rich 513.0× P/E leaves a thin margin of safety if growth slows. Return on equity is a soft 0.3%, capital efficiency trails higher-quality peers. A low Piotroski F-Score of 2/9 flags weaker financial health this cycle, worth understanding why before committing.